Business Description
Replimune Group Inc
NAICS : 325412
SIC : 2834
ISIN : US76029N1063
Description
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.68 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -23.5 | |||||
| 3-Year EPS without NRI Growth Rate | -27.1 | |||||
| 3-Year FCF Growth Rate | -27.7 | |||||
| 3-Year Book Growth Rate | -17.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 15.83 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.47 | |||||
| 9-Day RSI | 52.56 | |||||
| 14-Day RSI | 51.69 | |||||
| 6-1 Month Momentum % | 180 | |||||
| 12-1 Month Momentum % | 25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.11 | |||||
| Quick Ratio | 10.11 | |||||
| Cash Ratio | 9.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | -6.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -51.48 | |||||
| ROA % | -40.71 | |||||
| ROIC % | -317.32 | |||||
| ROC (Joel Greenblatt) % | -391.87 | |||||
| ROCE % | -42.43 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.24 | |||||
| Price-to-Tangible-Book | 2.24 | |||||
| EV-to-EBIT | -2.89 | |||||
| EV-to-EBITDA | -2.94 | |||||
| EV-to-Forward-Revenue | 12.55 | |||||
| EV-to-FCF | -3.15 | |||||
| Price-to-Net-Current-Asset-Value | 2.63 | |||||
| Price-to-Net-Cash | 2.71 | |||||
| Earnings Yield (Greenblatt) % | -34.6 | |||||
| FCF Yield % | -19.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Replimune Group Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.798 | ||
| Beta | 0.7 | ||
| Volatility % | 114.71 | ||
| 14-Day RSI | 51.69 | ||
| 14-Day ATR (€) | 0.365396 | ||
| 20-Day SMA (€) | 12.03 | ||
| 12-1 Month Momentum % | 25 | ||
| 52-Week Range (€) | 4.56 - 15 | ||
| Shares Outstanding (Mil) | 76.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Replimune Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Replimune Group Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Replimune Group Inc Frequently Asked Questions
What is Replimune Group Inc(FRA:7R8)'s stock price today?
The current price of FRA:7R8 is €11.30. The 52 week high of FRA:7R8 is €15.00 and 52 week low is €4.56.
When is next earnings date of Replimune Group Inc(FRA:7R8)?
The next earnings date of Replimune Group Inc(FRA:7R8) is 2025-02-07 Est..
Does Replimune Group Inc(FRA:7R8) pay dividends? If so, how much?
Replimune Group Inc(FRA:7R8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers